31 January 2012 - Diurnal, a company in the portfolio of British university commercialisation company Fusion IP Plc (LON:FIP), announced on Tuesday the successful completion of its clinical study for a new hydrocortisone formulation called Chronocort.

The trial on healthy volunteers involve...

 

 

 

You must be logged in to view the whole article.
Click here if you require signing up